FR3003172B1 - USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS - Google Patents

USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS

Info

Publication number
FR3003172B1
FR3003172B1 FR1352362A FR1352362A FR3003172B1 FR 3003172 B1 FR3003172 B1 FR 3003172B1 FR 1352362 A FR1352362 A FR 1352362A FR 1352362 A FR1352362 A FR 1352362A FR 3003172 B1 FR3003172 B1 FR 3003172B1
Authority
FR
France
Prior art keywords
inflammation
treatment
monoclonal antibodies
bacterial infections
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1352362A
Other languages
French (fr)
Other versions
FR3003172A1 (en
Inventor
Romeuf Christophe De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1352362A priority Critical patent/FR3003172B1/en
Application filed by LFB SA filed Critical LFB SA
Priority to US14/652,352 priority patent/US20160185847A1/en
Priority to PCT/FR2013/053120 priority patent/WO2014096672A1/en
Priority to EP13818329.8A priority patent/EP2931749B1/en
Priority to CA2894225A priority patent/CA2894225A1/en
Priority to EP19159751.7A priority patent/EP3514175A1/en
Priority to JP2015547130A priority patent/JP6461808B2/en
Publication of FR3003172A1 publication Critical patent/FR3003172A1/en
Application granted granted Critical
Publication of FR3003172B1 publication Critical patent/FR3003172B1/en
Priority to US16/436,537 priority patent/US20190375835A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR1352362A 2012-12-17 2013-03-15 USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS Expired - Fee Related FR3003172B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1352362A FR3003172B1 (en) 2013-03-15 2013-03-15 USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS
PCT/FR2013/053120 WO2014096672A1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
EP13818329.8A EP2931749B1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
CA2894225A CA2894225A1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
US14/652,352 US20160185847A1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
EP19159751.7A EP3514175A1 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
JP2015547130A JP6461808B2 (en) 2012-12-17 2013-12-17 Use of monoclonal antibodies in the treatment of inflammation and bacterial infections
US16/436,537 US20190375835A1 (en) 2012-12-17 2019-06-10 Use of monoclonal antibodies for the treatment of inflammation and bacterial infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1352362A FR3003172B1 (en) 2013-03-15 2013-03-15 USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS

Publications (2)

Publication Number Publication Date
FR3003172A1 FR3003172A1 (en) 2014-09-19
FR3003172B1 true FR3003172B1 (en) 2017-12-08

Family

ID=48856772

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1352362A Expired - Fee Related FR3003172B1 (en) 2012-12-17 2013-03-15 USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS

Country Status (1)

Country Link
FR (1) FR3003172B1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082137A4 (en) * 1998-05-06 2004-05-19 Univ Temple INVERSION OF A PRO-INFLAMMATORY REACTION BY THE LIGATION OF THE MACROPHAGE RECEPTOR Fc $ g (g) RI
FR2807767B1 (en) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
FR2858235B1 (en) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS
US20060051353A1 (en) * 2004-05-14 2006-03-09 Jean-Frederic Colombel Methods and compositions to evaluate antibody treatment response
JP5090366B2 (en) * 2005-12-16 2012-12-05 アイビーシー ファーマスーティカルズ，インク． Multivalent immunoglobulin bioactive assembly
PL2808343T3 (en) * 2007-12-26 2019-11-29 Xencor Inc Fc variants with altered binding to FcRn
JP2012504555A (en) * 2008-09-30 2012-02-23 ベイラー リサーチ インスティテュート Methods for reducing B helper T cells to treat autoimmune diseases
RU2013115927A (en) * 2010-09-10 2014-10-20 Апексиджен, Инк. ANTIBODIES AGAINST IL-1β AND METHODS OF APPLICATION
WO2013095738A2 (en) * 2011-09-27 2013-06-27 Mapp Biopharmaceutical, Inc. Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins

Also Published As

Publication number Publication date
FR3003172A1 (en) 2014-09-19

Similar Documents

Publication Publication Date Title
FR25C1001I2 (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
FR25C1016I1 (en) USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME
EP2968160A4 (en) IMMUNE MODIFICATION PARTICLES FOR THE TREATMENT OF INFLAMMATION
MA50082A (en) ENPP1 INHIBITORS AND THEIR USE FOR CANCER TREATMENT
EP2814509A4 (en) ANTIBODIES AGAINST INTEGRIN V 6 AND THEIR USE FOR THE TREATMENT OF CANCER
EP2983619A4 (en) SURGICAL ORIENTATION AND PLANNING SOFTWARE FOR THE TREATMENT OF ASTIGMATISM
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3390357A4 (en) BIARYLMONOBACTAM COMPOUNDS AND CORRESPONDING METHODS OF USE FOR THE TREATMENT OF BACTERIAL INFECTIONS
MA55697A (en) ANTIBODY MOLECULES FOR THE TREATMENT OF CANCER
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR THE TREATMENT OF CANCER
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
MA47604A (en) ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF LUNG CANCER
EP2652506A4 (en) USE OF ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER
MA43197A (en) BISPECIFIC ANTIBODY CONSTRUCTIONS FOR CDH3 AND CD3
EP3645039A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR FIBROSIS TREATMENT
EP3328429A4 (en) PEPTIDES AND ANTIBODIES FOR THE REMOVAL OF BIOFILMS
EP2860188A4 (en) POLYPEPTIDES AND ANTIBODIES FOR THE TREATMENT OF VBH INFECTION AND ASSOCIATED DISEASES
EP3512517A4 (en) USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
EP2652508A4 (en) USE OF ANTI-CXCL13 ANTI-CXCR5 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER
EP2838524A4 (en) COMPOSITIONS FOR TOPIC TREATMENT OF MICROBIAL INFECTIONS
EP2968470A4 (en) MODIFIED MULLERIAN INHIBITION SUBSTANCE PROTEINS (MIS) AND USES THEREOF FOR THE TREATMENT OF DISEASES
EP3573658A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
EP2967062A4 (en) DEETHYLHYDROXYCHLOROQUINE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION
EP3394098A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
FR3013184B1 (en) USE OF HYDROXYAPATITE FOR THE TREATMENT OF ESCA

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20231105